Company Profile
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
Latest News
Oil prices dip over 6% after US, Iran pause fighting over weekend
Fractus and Geotab settle U.S. patent litigation
Starcore Reports Year End 2026 Results
Tredence Launches Domain Native Forward Deployed Engineering to Close the Last Mile of Enterprise AI
Earnings To Watch: Corning (GLW) Reports Q2 Results Tomorrow
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.cosmohealthconfidence.com |
| Market Cap | 1.09B |
| Forward P/E | 19.1 |
| Dividend Rate | 1.92 |
| Dividend Yield | 3.01% |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -0.35 |
| Forward EPS | 3.33 |
| Book Value | 27.73 |
| Price-to-Book | 2.29 |
| Enterprise-to-Revenue | 8.86 |
| Enterprise-to-EBITDA | 182.37 |
| Ex-Dividend Date | 04/24/2026 |
| Dividend Date | 06/06/2025 |
| Earnings Date | 07/23/2026 |
| Earnings Call Date | 07/23/2026 |
| Earnings Average | -0.03 |
| Earnings Low | -0.03 |
| Earnings High | -0.03 |
| Revenue Average | 24.52M |
| Revenue Low | 24.52M |
| Revenue High | 24.52M |